Highlights
1 patent
About
Tumor Immune Conditioning Agents
Moya Bio is developing a novel class of tumor immune conditioning agents. The company's inhibitors of the FAT10 pathway are designed to increase the impact of immunotherapy by sensitizing the tumor to immune-mediated cytotoxicity, to benefit additional patient populations. Moya Bio's translational data demonstrates a correlation between FAT10 down regulation, increased T-cell infiltration into the tumor microenvironment, and inhibition of tumor growth. The molecular mechanism underlying Moya's FAT10 inhibition platform supports a synergistic effect with immune checkpoint inhibitors, which is expected to enhance their clinical efficacy.
Identity
| Name | Moya Bio |
|---|---|
| Slug | moya-bio |
| Type / kind | startup |
| Source _id | agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICA4NSu4YsLDA |
Status
| Status | inactive |
|---|---|
| Status reason | Non Active, Nov 2024 ceased to operate |
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ city | |
| HQ address | Ilan Ramon Street 2, Ness Ziona, Israel |
Classifications
Primary sector Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsMolecules
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticalsBiotechnology
Business models
B2B
Tags
medical-technologiesimmunotherapyhospitalsbiotechnologycancerlife-sciences
Funding
| Total raised | $3.0M |
|---|---|
| Current stage | Seed |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}